Patents by Inventor Emma Hickman

Emma Hickman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ORGANIC COMPOSITIONS TO TREAT Beta-ENaC-RELATED DISEASES
    Publication number: 20140107179
    Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
    Type: Application
    Filed: October 1, 2013
    Publication date: April 17, 2014
    Applicant: Novartis AG
    Inventors: Antonin DE FOUGEROLLES, John L. DIENER, Emma HICKMAN, Gregory HINKLE, Stuart MILSTEIN, Anne-Marie PULICHINO, Andrew Griffin SPRAGUE
  • Organic compositions to treat Beta-ENaC-related diseases
    Patent number: 8598335
    Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: December 3, 2013
    Assignee: Novartis AG
    Inventors: Antonin De Fougerolles, John Diener, Emma Hickman, Gregory Hinkle, Stuart Milstein, Anne-Marie Pulichino, Andrew Griffin Sprague
  • Organic Compositions to Treat Beta-ENaC-Related Diseases
    Publication number: 20130012571
    Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
    Type: Application
    Filed: September 13, 2012
    Publication date: January 10, 2013
    Applicant: NOVARTIS AG
    Inventors: Antonin DE FOUGEROLLES, John L. DIENER, Emma HICKMAN, Gregory HINKLE, Stuart MILSTEIN, Anne-Marie PULICHINO, Andrew SPRAGUE
  • Organic compositions to treat Beta-ENaC-related diseases
    Patent number: 8344129
    Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
    Type: Grant
    Filed: January 23, 2012
    Date of Patent: January 1, 2013
    Assignee: Novartis AG
    Inventors: Antonin De Fougerolles, John L. Diener, Emma Hickman, Gregory Hinkle, Stuart Milstein, Anne-Marie Pulichino, Andrew Griffin Sprague
  • Organic compositions to treat beta-ENaC-related diseases
    Patent number: 8344131
    Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
    Type: Grant
    Filed: January 23, 2012
    Date of Patent: January 1, 2013
    Assignee: Novartis AG
    Inventors: Antonin De Fougerolles, John L. Diener, Emma Hickman, Gregory Hinkle, Stuart Milstein, Anne-Marie Pulichino, Andrew Griffin Sprague
  • Organic compositions to treat beta-ENaC-related diseases
    Patent number: 8344127
    Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
    Type: Grant
    Filed: April 20, 2011
    Date of Patent: January 1, 2013
    Assignee: Novartis AG
    Inventors: Antonin De Fougerolles, John L. Diener, Emma Hickman, Gregory Hinkle, Stuart Milstein, Anne-Marie Pulichino, Andrew Sprague
  • Organic compositions to treat Beta-ENaC-related diseases
    Patent number: 8344130
    Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
    Type: Grant
    Filed: January 23, 2012
    Date of Patent: January 1, 2013
    Assignee: Novartis AG
    Inventors: Antonin De Fougerolles, John L. Diener, Emma Hickman, Gregory Hinkle, Stuart Milstein, Anne-Marie Pulichino, Andrew Griffin Sprague
  • Organic Compositions to Treat Beta-ENaC-Related Diseases
    Publication number: 20120122960
    Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
    Type: Application
    Filed: January 23, 2012
    Publication date: May 17, 2012
    Applicant: NOVARTIS AG
    Inventors: Antonin DE FOUGEROLLES, John L. DIENER, Emma HICKMAN, Gregory HINKLE, Stuart MILSTEIN, Anne-Marie PULICHINO, Andrew SPRAGUE
  • Organic Compositions to Treat Beta-ENaC-Related Diseases
    Publication number: 20120115934
    Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
    Type: Application
    Filed: January 23, 2012
    Publication date: May 10, 2012
    Applicant: NOVARTIS AG
    Inventors: Antonin DE FOUGEROLLES, John L. DIENER, Emma HICKMAN, Gregory HINKLE, Stuart MILSTEIN, Anne-Marie PULICHINO, Andrew SPRAGUE
  • Organic Compositions to Treat Beta-ENaC-Related Diseases
    Publication number: 20120115933
    Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
    Type: Application
    Filed: January 23, 2012
    Publication date: May 10, 2012
    Inventors: Antonin DE FOUGEROLLES, John L. DIENER, Emma HICKMAN, Gregory HINKLE, Stuart MILSTEIN, Anne-Marie PULICHINO, Andrew SPRAGUE
  • RNAi inhibition of alpha-ENaC expression
    Patent number: 8168606
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: May 1, 2012
    Assignee: Novartis AG
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans Peter Vornlocher
  • RNAi inhibition of alpha-ENaC expression
    Patent number: 8119612
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: February 21, 2012
    Assignee: Novartis AG
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans Peter Vornlocher
  • Organic Compositions to Treat Beta-ENaC-Related Diseases
    Publication number: 20110263681
    Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
    Type: Application
    Filed: April 20, 2011
    Publication date: October 27, 2011
    Applicant: NOVARTIS AG
    Inventors: Antonin DE FOUGEROLLES, John L. DIENER, Emma HICKMAN, Gregory HINKLE, Stuart MILSTEIN, Anne-Marie PULICHINO, Andrew SPRAGUE
  • RNAi inhibition of alpha-ENaC expression
    Patent number: 7943592
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: May 17, 2011
    Assignee: Novartis AG
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans Peter Vornlocher
  • RNAi inhibition of alpha-ENaC expression
    Patent number: 7939508
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: May 10, 2011
    Assignee: Novartis AG
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans Peter Vornlocher
  • RNAi Inhibition of Alpha-ENaC Expression
    Publication number: 20100216972
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Application
    Filed: April 30, 2010
    Publication date: August 26, 2010
    Inventors: Gino VAN HEEKE, Emma HICKMAN, Henry Luke DANAHAY, Pamela TAN, Anke GEICK, Hans-Peter VORNLOCHER
  • RNAi Inhibition of Alpha-ENaC Expression
    Publication number: 20100216971
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Application
    Filed: April 30, 2010
    Publication date: August 26, 2010
    Inventors: Gino VAN HEEKE, Emma HICKMAN, Henry Luke DANAHAY, Pamela TAN, Anke GEICK, Hans-Peter VORNLOCHER
  • RNAi Inhibition of Alpha-ENaC Expression
    Publication number: 20100210514
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Application
    Filed: April 30, 2010
    Publication date: August 19, 2010
    Inventors: Gino VAN HEEKE, Emma HICKMAN, Henry Luke DANAHAY, Pamela TAN, Anke GEICK, Hans-Peter VORNLOCHER
  • RNAi Inhibition of Alpha-ENaC Expression
    Publication number: 20100210513
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Application
    Filed: April 30, 2010
    Publication date: August 19, 2010
    Inventors: Gino VAN HEEKE, Emma HICKMAN, Henry Luke DANAHAY, Pamela TAN, Anke GEICK, Hans-Peter VORNLOCHER
  • RNAi Inhibition of Alpha-ENaC Expression
    Publication number: 20100190714
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Application
    Filed: January 6, 2010
    Publication date: July 29, 2010
    Inventors: Gino VAN HEEKE, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans-Peter Vornlocher